PLOS ONE | https://doi.org/10.1371/journal.pone.0185526 September 28, 2017
Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisboa, Portugal
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Practical Guidance for collaborative interventions
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Teymur Noori, with technical support from Andrew J. Amato-Gauci, Anastasia Pharris, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Teymur Noori. Report review was provided by Andrew J. Amato-Gauci, Anastasia Pharris, Annabelle Gourlay, Amanda Mocroft, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
BMC Health Services Research (2017) 17:623 DOI 10.1186/s12913-017-2567-7
Lessons from the STEP-TB Project.
Accessed November 2017.
Lancet Planet Health 2017 Published Online November 6, 2017 http://dx.doi.org/10.1016/S2542-5196(17)30141-9
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more